Search Results - "Helfrich, Hanne"

TP53 mutation and survival in aggressive B cell lymphoma by Zenz, Thorsten, Kreuz, Markus, Fuge, Maxi, Klapper, Wolfram, Horn, Heike, Staiger, Annette M, Winter, Doris, Helfrich, Hanne, Huellein, Jennifer, Hansmann, Martin-Leo, Stein, Harald, Feller, Alfred, Möller, Peter, Schmitz, Norbert, Trümper, Lorenz, Loeffler, Markus, Siebert, Reiner, Rosenwald, Andreas, Ott, German, Pfreundschuh, Michael, Stilgenbauer, Stephan

“…TP53 is mutated in 20-25% of aggressive B-cell lymphoma (B-NHL). To date, no studies have addressed the impact of TP53 mutations in prospective clinical trial…”
Get full text

MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma by Hüllein, Jennifer, Słabicki, Mikołaj, Rosolowski, Maciej, Jethwa, Alexander, Habringer, Stefan, Tomska, Katarzyna, Kurilov, Roma, Lu, Junyan, Scheinost, Sebastian, Wagener, Rabea, Huang, Zhiqin, Lukas, Marina, Yavorska, Olena, Helfrich, Hanne, Scholtysik, René, Bonneau, Kyle, Tedesco, Donato, Küppers, Ralf, Klapper, Wolfram, Pott, Christiane, Stilgenbauer, Stephan, Burkhardt, Birgit, Löffler, Markus, Trümper, Lorenz H, Hummel, Michael, Brors, Benedikt, Zapatka, Marc, Siebert, Reiner, Kreuz, Markus, Keller, Ulrich, Huber, Wolfgang, Zenz, Thorsten

“…Oncogenic MYC activation promotes proliferation in Burkitt lymphoma, but also induces cell-cycle arrest and apoptosis mediated by p53, a tumor suppressor that…”
Get full text

DNA damage–induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing by Mohr, Julia, Helfrich, Hanne, Fuge, Maxi, Eldering, Eric, Bühler, Andreas, Winkler, Dirk, Volden, Matthias, Kater, Arnon P., Mertens, Daniel, Te Raa, Doreen, Döhner, Hartmut, Stilgenbauer, Stephan, Zenz, Thorsten

“…The DNA damage pathway plays a central role in chemoresistance in chronic lymphocytic leukemia (CLL), as indicated by the prognostic impact of TP53 and ATM…”
Get full text

Treatment resistance in chronic lymphocytic leukemia-the role of the p53 pathway by Zenz, Thorsten, Mohr, Julia, Edelmann, Jennifer, Sarno, Antonio, Hoth, Patrick, Heuberger, Maria, Helfrich, Hanne, Mertens, Daniel, Döhner, Hartmut, Stilgenbauer, Stephan

“…The importance of studying p53 pathway defects in chronic lymphocytic leukemia (CLL) has been promoted by the demonstration of the fundamentally different…”
Get full text

TP53 Mutation Is an Independent Predictor of Poor Survival in Untreated Patients with CD20+ Aggressive B-Cell Lymphoma: Analysis within the Ricover-60 Trial by Zenz, Thorsten, Kreuz, Markus, Winter, Doris, Helfrich, Hanne, Fuge, Maxi, Horn, Heike, Richter, Julia, Siebert, Reiner, Truemper, Lorenz, Schmitz, Norbert, Loeffler, Markus, Klapper, Wolfram, Rosenwald, Andreas, Döhner, Hartmut, Pfreundschuh, Michael, Ott, German, Stilgenbauer, Stephan

“…Abstract 546 TP53 is commonly mutated across lymphoma entities. TP53 mutations have been found in 20–25 % of aggressive B-cell lymphomas and most studies…”
Get full text

TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG by Zenz, Thorsten, Hoth, Patrick, Busch, Raymonde, Helfrich, Hanne, Winkler, Dirk, Bühler, Andreas, Patten, Nancy, Truong, Sim, Wu, Lin, Fingerle-Rowson, Günther, Fischer, Kirsten, Fink, Anna-Maria, Jäger, Ulrich, Böttcher, Sebastian, Kneba, Michael, Wenger, Michael K., Mendila, Myriam, Hallek, Michael, Döhner, Hartmut, Stilgenbauer, Stephan

“…Abstract 1267▪▪This icon denotes an abstract that is clinically relevant. Poster Board I-289 The international multicenter randomized CLL8 trial evaluated 1st…”
Get full text